Stanford builds virtual biotech run by 37,000 AI scientist agents, with real drug discovery results
Dr_Singularity · x · 2026-09-20
Stanford Medicine's James Zou lab spun out a virtual biotech company staffed entirely by 37,000 AI agents covering the full drug development pipeline, with no human employees.
- The agents analyzed 50,000 clinical trials in under a week, uncovering biological signals linked to drug success
- They independently designed a B7-H3 lung cancer therapy strategy that a pharma company later advanced into human testing
- The team argues such digital workforces could scale to millions of agents, dramatically accelerating drug discovery
More from AGI Musings
- Newsweek op-ed: US should fund hospitals and universities in federated AI learning — Saul_Loveman · 2026-11-12
- 10-line deterministic polynomial-time primality test relies on OpenAI's recent quasi-GRH result, making AKS obsolete — fortnow · 2026-11-11
- AI2027 Author Kokotajlo Shifts AGI Median Timeline to Around 2030 — JacquesThibs · 2026-11-11
- Ron Bodkin: automated research taste advances faster than expected, but the evidence is weak — ronbodkin · 2026-11-11
- Should devs still hand-write code? Author proposes 1,000-hour baseline before AI agents — bendee983 · 2026-11-11
- DEF CON panel with Bruce Schneier and Google security VP posted: scaling laws and open weights — JasonDClinton · 2026-11-11